RealPennies

Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox


What you feel with this company ? Are you willing to
10
2
2
Bristol-Myers Squibb Co.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887
Last $51.18 USD
Change Today -0.53 / -1.02%
Volume 6.0M
As of 4:15 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$51.70
Previous Close
$51.71
Day High
$51.96
Day Low
$51.14
52 Week High
03/6/14 - $57.49
52 Week Low
09/30/13 - $45.70
Market Cap
84.9B
Average Volume 10 Days
5.9M
EPS TTM
$1.78
Shares Outstanding
1.7B
EX-Date
10/1/14
P/E TM
28.7x
Dividend
$1.44
Dividend Yield
2.79%
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

Cancer Survivor Numbers Triple From 40 Years Ago: Report
Uber Technologies, Bristol-Myers: Intellectual Property
Bristol-Myers Sues Merck Over Cancer Immunotherapy Patent
Merck Wins U.S. Approval for Melanoma Immunotherapy
Novartis Rises Most in Three Years on Heart-Drug Trial

bristol-myers squibb co (BMY) Related News

It's Not Just Disruption: More Management Wisdom You Should Doubt
'Miracle' Data Could Lead to Cancer Cures
Buying Prescription Drugs Online Without Getting Burned
Bid & Ask: The Deals of the Week

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Announces Positive Results from CheckMate - 037

Bristol-Myers Squibb Company announced positive results from CheckMate - 037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab). Based on a planned interim analysis of the co-primary endpoint, the objective response rate (ORR) was 32% (95% CI = 24, 41) in the Opdivo arm (n=120) and 11% (95% CI = 4, 23) in the ICC reference arm (n=47) in patients with at least six months of follow up. The majority (95%) of responses were ongoing in the Opdivo arm and the median duration of response was not reached. ORR was based on RECIST criteria as evaluated by an independent radiologic review committee (IRRC). Safety was reported on all patients treated in the Opdivo (n=268) and ICC (n=102) arms. The majority of Opdivo treatment-related adverse events (AEs) were Grade 1/2 and managed using recommended treatment algorithms. Grade 3/4 drug-related AEs were less frequent for the Opdivo arm (9% versus 31% of patients treated chemotherapy). Serious Grade 3/4 drug-related AEs were reported in 5% and 9% of patients treated with Opdivo and ICC, respectively. There was no Grade 3/4 pneumonitis (inflammatory lung disease) with Opdivo. Discontinuations due to drug-related AEs, of any grade, occurred in 2% of Opdivo-treated patients and 8% of patients administered ICC. There were no deaths related to study drug toxicity. In June, Bristol-Myers Squibb announced that a randomized blinded comparative Phase 3 study evaluating Opdivo versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma (CheckMate -066) was stopped early because an analysis conducted by the independent Data Monitoring Committee showed evidence of superior overall survival in patients receiving Opdivo compared to the control arm. The Company is working with investigators on the future presentation and publication of the results from CheckMate -066.

Bristol-Myers Squibb to Build New Office in Lawrenceville, New Jersey

Bristol-Myers Squibb Company announced plans to build a 650,000 sqft office building on company-owned land at the intersection of Princeton Pike and Interstate 295 in Lawrenceville, New Jersey. Construction is expected to begin this fall and the new facility is expected to open by the end of 2016. The new facility is part of the company's broader strategic plan to modernize its workspace to enable greater collaboration, increase technological capabilities and enhance productivity. The new facility will allow the company to consolidate operations currently located in leased office space at 777 Scudders Mill Road in Plainsboro Township and at Nassau Park Boulevard in West Windsor Township. The Princeton Pike location was purchased by Bristol-Myers Squibb from RCN Corp.

Bristol-Myers Squibb Company Announces the Amendment to the Bylaws

On September 16, 2014, Bristol-Myers Squibb Company amended the Bylaws to reflect recent statutory and case law developments, to reflect best practices and for clarification purposes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $51.18 USD -0.53

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.76 USD -0.76
Actavis plc $241.28 USD -3.11
Celgene Corp $94.78 USD -0.86
Novo Nordisk A/S kr282.00 DKK -2.00
Thermo Fisher Scientific Inc $121.70 USD -0.30
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 32.1x
Price/Sales 5.3x
Price/Book 5.6x
Price/Cash Flow 31.9x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer
[Business Wire] - Bristol-Myers Squibb Company today announced that the European Medicines Agency has validated for review the Marketing Authorization Application for nivoluma
  Read More...
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers, Johnson & Johnson, AbbVie and Medivation
  Read More...
3:08 am Bristol-Myers reports positive Phase 3 data for Opdivo in advanced melanoma patients previously treated with Yervoy
  Read More...
INNATE PHARMA: Third DSMB for EffiKIR trial recommends continuation as planned
[Thomson Reuters ONE] - Marseille, France, September 25, 2014 Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for ...
  Read More...